Calcium-based phosphate binders and chronic kidney disease

The Lancet

Volumn 383, Issue 9913, 2014, Pages 216-

  Hiremath, Swapnil ^a   Akbari, Ayub ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PHOSPHATE BINDING AGENT;

CHRONIC KIDNEY DISEASE; CLASSIFICATION; CLINICAL PROTOCOL; DIALYSIS; HUMAN; INTENTION TO TREAT ANALYSIS; LETTER; MORTALITY; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

EID: 84892612061     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60070-2     Document Type: Letter

References (5)

1. Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013; 382: 1268-77.
2. Suki WN. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. J Ren Nutr 2008; 18: 91-98.
3. Nuesch E, Trelle S, Reichenbach S, et al. Small study effects in meta-analyses of osteo-arthritis trials: meta-epidemiological study. BMJ 2010; 341: c3515.
4. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455-63.
5. DiIorio D. Correction. http://cjasn.asnjournals. org/content/7/8/1370 (accessed July 31, 2013).